Industry: Health Care – Biotechnology: Pharmaceutical Preparations
Stock Symbol: SEPN – NASDAQ
Animal Usage: Animal Testing
Septerna, Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.
Supporting Evidence:
The company confirms in corporate disclosures that it utilizes animal subjects for product testing.
“SEP-786 is an oral small molecule Parathyroid Hormone 1 Receptor (PTH1R) agonist in development for the treatment of hypoparathyroidism. In preclinical studies, SEP-786 has been observed to be generally well-tolerated and has demonstrated potent and selective activation of PTH1R in cell-based models, and in a preclinical animal model of hypoparathyroidism, SEP-786 controlled serum calcium levels within the normal range over a 28-day dosing period.” Read the article for more details
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Company Website: https://www.septerna.com